Search results for " GAS"

showing 10 items of 4643 documents

A rare rarity: neuroendocrine tumor of the esophagus

2019

Abstract Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the mo…

0301 basic medicinemedicine.medical_specialtyCarcinoid tumorsesophageal neoplasmsNeuroendocrine tumorsSmall-cell carcinomaGastroenterology03 medical and health sciences0302 clinical medicinegastroenteropancreatic NETInternal medicineEpidemiologymedicinerisk factorsesophageal NEC; gastroenteropancreatic NET; large cell esophageal NEN; MANEC; small cell carcinoma; delayed diagnosis; esophageal neoplasms; humans; neuroendocrine tumors; prognosis; rare diseases; risk factorsEsophagusStage (cooking)esophageal NECdelayed diagnosishumanssmall cell carcinomabusiness.industryLarge cellMANECrare diseasesHematologymedicine.diseaseDysphagia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesislarge cell esophageal NENprognosismedicine.symptomneuroendocrine tumorsbusiness
researchProduct

Reply to: “Performance status in patients with HCC: New kid on the block”

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularPsychometricsHepatologyPerformance statusbusiness.industryLiver NeoplasmsMEDLINESurgery03 medical and health sciences030104 developmental biology0302 clinical medicineBlock (telecommunications)HumansMedicine030211 gastroenterology & hepatologyIn patientbusinessJournal of Hepatology
researchProduct

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsClinical Decision-MakingDIRECT ACTING ANTIVIRALSAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHepatologybusiness.industryIncidencePatient SelectionLiver NeoplasmsHepatitis C ChronicHepatologymedicine.diseaseLiver TransplantationTreatment Outcome030104 developmental biologyHepatocellular carcinomaCancer research030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

Hepatic benefits of HCV cure

2020

Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to improved outcomes at all stages of liver disease. However, available data suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all patients with chronic hepatitis C should be treated before they develop advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces the risk of hepatic events (e.g. decompensation and hepatocellular carcinoma [HCC]) and improves survival, further progression of liver disease and adverse outcomes, including hepatic deaths, cannot be entirely avoided…

0301 basic medicinemedicine.medical_specialtyCirrhosisHepatocellular carcinomaPortal venous pressureSurvival.Chronic liver diseaseGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineDecompensationCirrhosiHepatologybusiness.industryHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologyHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologybusiness
researchProduct

2017

Background and aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at-risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population-based Dallas Heart Study (DHS). Results Hep…

0301 basic medicinemedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver disease3. Good health03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseaseInternal MedicineMedicine030211 gastroenterology & hepatologySteatosisbusinessJournal of Internal Medicine
researchProduct

Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)

2020

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C stage hepatocellular carcinoma (HCC) is understudied. Patients with HCC have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less well defined. The presence of active HCC before the initiation of DAA treatment is reported to be a predictor of DAA failure, and studies in patients without HCC have demonstrated that improvements in cirrhosis complications were lower or absent after DAA failure. Even if viral eradication is achieved using DAAs, reversal of liver function impairme…

0301 basic medicinemedicine.medical_specialtyCirrhosisrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentDecision MakingLiver transplantationAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineMedicineHumansStage (cooking)HCCIntensive care medicineDAANeoplasm StagingAntiviral Agent...Hepatologybusiness.industryLiver NeoplasmsPalliative CareCancerHepatitis C Chronicmedicine.diseaseBCLC Stage030104 developmental biologyBCLC-Dliver functionHepatocellular carcinoma030211 gastroenterology & hepatologyLiver functionbusinessLiver cancerBCLC-BBCLC-CHuman
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

2015

BACKGROUND There is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). OBJECTIVE The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. METHODS The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following t…

0301 basic medicinemedicine.medical_specialtyConsensusAttitude of Health PersonnelAlternative medicineDelphi methodGastroenterologyScientific evidence03 medical and health sciences0302 clinical medicineInternal medicinePhysiciansSurveys and QuestionnairesmedicineImmunology and AllergyHumansDisease management (health)Thiopurine methyltransferasebiologybusiness.industryRemission InductionGastroenterologyDisease ManagementEvidence-based medicineDiscontinuation030104 developmental biologyFamily medicinePractice Guidelines as Topicbiology.protein030211 gastroenterology & hepatologyColitis UlcerativeWorking groupbusinessInflammatory bowel diseases
researchProduct

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

2021

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in nonalcoholic fatty liver disease (NAFLD), where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collect…

0301 basic medicinemedicine.medical_specialtyFIBROSIS STAGEBiomedical ResearchConsensusClinical SciencesImmunologyDiseaseMedical Biochemistry and MetabolomicsDIAGNOSISVALIDATIONArticle03 medical and health sciences0302 clinical medicineClinical ResearchNon-alcoholic Fatty Liver DiseaseEpidemiologyHealth caremedicineElectronic Health RecordsHumansGeneralizability theoryALGORITHMFATTY LIVER-DISEASEStatement (computer science)Gastroenterology & HepatologyHepatologybusiness.industryMORTALITYComparabilityClinical CodingReference Standards3. Good healthGood Health and Well Being030104 developmental biology3121 General medicine internal medicine and other clinical medicineFamily medicineInclusion and exclusion criteria030211 gastroenterology & hepatologyPatient SafetybusinessPsychologyREAL-WORLDCoding (social sciences)Hepatology
researchProduct